Non-Invasive Prenatal Screening (NIPT)

Non-invasive prenatal screening test for Down’s syndrome and other serious genetic conditions

What is the NIPT test?

The NIPT test is a non-invasive prenatal test (NIPT) for pregnant women which estimates the risk of a fetus having Down syndrome or some other genetic diseases. The NIPT test is an advanced screening test that is carried out on a small maternal blood sample. Pregnant women can expect test results from their healthcare provider within 14 days from sample receipt.
The NIPT test estimates the risk of a fetus having Down syndrome (Trisomy 21), Edwards syndrome (Trisomy 18) and Patau syndrome (Trisomy 13). Trisomies occur when three, instead of the usual two, copies of a chromosome are present. Edwards and Patau syndromes are much rarer than Down but are very serious and many affected babies do not survive. If fetal sex determination is requested, the accuracy is greater than 99%. In rare cases a “sex determination failure” result may be reported if there is insufficient data to support the sex determination analysis. A “sex determination failure“ does not impact the trisomy result.

Safe Non-invasive with no risk of miscarriage.

Fast Provides results within 10-14days from sample receipt.

Accurate Greater than 99% detection of trisomy conditions and fetal sex determination.

Simple Uses a simple maternal blood sample.

Reliable quality The NIPT test is provided by high quality laboratory at Bumrungrad hospital using the IONA® test which is a regulated, CE marked test.

During pregnancy, the placenta leaks cell-free DNA which circulates in the maternal bloodstream. As a result, a maternal blood sample contains a mixture of fetal-placental and maternal circulating cell-free DNA. The NIPT test directly measures the amount of this cell-free DNA and can detect small changes in the DNA ratio between the maternal and fetal cell-free DNA when a fetal trisomy 21, 18 or 13 is present.


Traditional first trimester screening offered during pregnancy is called the First Trimester Combined Test (FTCT). This is an ultrasound scan to measure the nuchal translucency (NT) and a blood test. This method is less accurate for detecting fetal trisomies (85-90%), but can help with the early detection of both maternal and fetal complications. The IONA® is the only NIPT that has the option to incorporate the result of the FTCT into the calculation to offer you the most comprehensive and tailored prenatal screen. You can still get accurate trisomy screening even without the FTCT result. Many women choose to have an IONA® test from 10 weeks gestation following an ultrasound, which is an essential requirement for IONA®. The IONA® test has a higher detection rate than the current FTCT offered to pregnant women. This means that fewer pregnant women will undergo unnecessary invasive follow-up procedures such as amniocentesis or CVS* which can be stressful, painful and may carry a small risk of miscarriage.
  • From 10 weeks gestation
  • Singleton or twin pregnancies
  • IVF, donor egg or surrogate pregnancies
  • Low risk: It is very unlikely your pregnancy is affected by trisomy 21, 18 or 13.
  • High risk: Your pregnancy is at increased risk for trisomy 21, 18 or 13 and the result should be confirmed by a follow-up invasive procedure such as amniocentesis.
  • No result: In rare cases there is insufficient fetal DNA in the sample to obtain a result. You may be asked by your healthcare provider for an additional blood sample.

An example scenario showing the difference between the screening tests:


Doctors Related

Related Centers

Women's Center

Learn more

Related Packages

Rating score 9.20 of 10, based on 5 vote(s)

Related Health Blogs